For example, BRAF inhibition alone using vemurafenib demonstrated striking lack of efficacy in colorectal cancer patients, in contrast to BRAFmut melanomas, and produced a response rate of only 5% [45]. This evidence concerns the gene BRAF and colorectal cancer.